Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. reports commercial, clinical and regulatory developments for its bioengineered human tissue platform. The company’s first FDA-approved product, Symvess, is an acellular tissue engineered vessel indicated for treatment of extremity vascular trauma, while other ATEV applications remain part of its broader regenerative medicine pipeline.
Recurring updates include Symvess commercialization, hospital access and distribution arrangements, international regulatory submissions, and clinical work in arteriovenous access for hemodialysis patients. Humacyte also reports quarterly financial results, business-development activity, financing actions and leadership changes tied to its transition from platform development to commercial-stage biotechnology operations.
Humacyte (Nasdaq:HUMA) priced an underwritten public offering of 47,619,048 shares of common stock at $1.05 per share, targeting approximately $50 million in gross proceeds. Closing is expected around June 12, 2026, with a 30-day option for underwriters to buy up to 7,142,857 additional shares.
All shares are offered by Humacyte. Net proceeds are earmarked to commercialize Symvess, support a planned BLA supplement for a hemodialysis indication, advance pipeline candidates, and for working capital and general corporate purposes. Barclays, BTIG and Titan Partners act as joint book-running managers.
Humacyte (Nasdaq:HUMA) has launched an underwritten public offering of common stock, with all shares sold by the company and a 30-day option for underwriters to buy up to 15% additional shares. Proceeds are expected to fund Symvess commercialization, a planned hemodialysis BLA supplement, pipeline development, and general corporate purposes.
Humacyte (Nasdaq:HUMA) reported positive interim Phase 3 V012 results for its acellular tissue engineered vessel (ATEV) in female dialysis access patients.
The ATEV met the primary endpoint, delivering an average of 220 catheter-free days vs 129 for autologous AV fistula (difference 91 days, p=0.00070). Infection rates were 6 vs 23 per 100 patient years, with no access-associated infections in ATEV patients. Enrollment will stop at 120 patients, and Humacyte plans a supplemental BLA filing with the FDA in 2H 2026 for adult end-stage kidney disease patients at increased risk of AV fistula maturation failure.
Humacyte (Nasdaq:HUMA) presented research at the 2026 VASA dialysis symposium showing its acellular tissue engineered vessel (ATEV) maintained long-term structural integrity and showed self-repair after repeated cannulations, with smooth muscle cell repopulation, tissue remodeling, and evidence of greater resistance to bacterial infection versus ePTFE grafts in explants up to 5.5 years.
Humacyte expects top-line interim results from the V012 Phase 3 dialysis access study, focused on female ESRD patients, on June 11, 2026, and plans a potential sBLA for AV access in the second half of 2026.
Humacyte (Nasdaq:HUMA) announced that its bioengineered vessel product Symvess is now under contract with the U.S. Department of Veterans Affairs’ Strategic Acquisition Center (SAC) through the Surgical Implant – Next Generation (SING) program.
This contract makes Symvess more easily accessible to 170 VA hospitals, SAC’s preferred sourcing sites, after SAC’s surgical committee product and value vetting. Symvess received FDA approval in December 2024 for extremity vascular trauma; for all other uses, it remains investigational and unapproved.
Humacyte (Nasdaq:HUMA) reported first quarter 2026 results and a business update. Symvess sales reached $0.5 million (29 units), up from $0.1 million (5 units) a year earlier. Contract revenue fell to $2,000 from $0.4 million.
The company received a $1.475 million minimum Symvess purchase commitment in Saudi Arabia, Israeli review acceptance for Symvess, and new U.S. Department of Defense funding. An interim Phase 3 hemodialysis readout is planned for June 11, 2026. A workforce restructuring is expected to save $14.3 million through 2026, with estimated $0.8 million in one-time charges. Net loss was $17.6 million, and cash, cash equivalents and restricted cash totaled $48.9 million at March 31, 2026.
Humacyte (Nasdaq:HUMA) appointed vascular surgeon Dr. Todd E. Rasmussen as Chief Surgical Officer. He will provide peer-to-peer scientific support, medical education, and technical insights to help optimize safe and effective implantation of Humacyte’s bioengineered vascular products, including Symvess, as clinical adoption and pipeline indications advance.
Dr. Rasmussen brings 28 years of U.S. Air Force experience, leadership roles at Mayo Clinic, and more than 350 peer-reviewed publications. He will maintain his clinical, educational, and administrative responsibilities at Mayo Clinic while serving separately at Humacyte.
Humacyte (Nasdaq: HUMA) will release its 2026 first quarter financial results for the period ended March 31, 2026 on May 13, 2026 and will host a webcast and conference call at 8:00 a.m. ET for a corporate and financial update.
The company is a commercial-stage developer of acellular, bioengineered human tissues; its ATEV received FDA approval in December 2024 for vascular trauma and continues in late-stage trials for AV access and PAD. Webcast and dial-in details are provided for investors.
Humacyte (Nasdaq: HUMA) will host a virtual key opinion leader event on April 28, 2026 at 8:00 AM ET to discuss the unmet need and treatment landscape for hemodialysis patients with end-stage renal disease and provide an overview of its Acellular Tissue Engineered Vessel (ATEV) in arteriovenous access.
The event features KOLs Prabir Roy-Chaudhury, MD, PhD, FASN, and Mohamad A. Hussain, MD, PhD, RPVI, FAHA, FRCSC, FACS, and will include a live Q&A. The ATEV remains investigational for uses beyond the FDA extremity vascular trauma approval; interim V012 Phase 3 top-line results are expected this quarter.
Humacyte (Nasdaq: HUMA) on April 24, 2026 realigned ex-U.S. commercial rights to Symvess through an amended distribution agreement with Fresenius Medical Care. The amendment grants Humacyte exclusive distribution rights outside the U.S., with Fresenius entitled to low-single-digit royalties on Humacyte's net non-U.S. sales. U.S. distribution terms remain unchanged. The realignment is intended to support Humacyte's planned international expansion, advance discussions with potential corporate partners for indication-specific and regional rights, and enable previously announced initiatives in the Kingdom of Saudi Arabia and Israel. For uses beyond the FDA-approved extremity vascular trauma indication, Symvess remains investigational and is not approved for sale by the FDA or other regulators.